Aclaris Therapeutics

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence Read More

Coatesville website